Xenon Pharmaceuticals Inc. — Director's Dealing 2021

May 26, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Xenon Pharmaceuticals Inc. (XENE)
CIK: 0001582313
Period of Report: 2021-05-24

Reporting Person: PIMSTONE SIMON N. (Director, CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-05-24	Common Shares	M	22633	$3.76	Acquired	232819	Direct
2021-05-24	Common Shares	F	5076	$19.17	Disposed	227743	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-05-24	Stock Option (Right to Buy)	$3.76	M	22633	Disposed	2021-05-28	Common Shares (22633)	Direct

Footnotes

F1: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.

F2: Represents the closing price of the Company's common shares on May 21, 2021, which was converted to a Canadian dollar amount for purposes of net settlement calculations.

F3: 25% of the shares subject to the Option vested on the one year anniversary of January 1, 2011 (the "2011 Vesting Commencement Date") and thereafter 1/48th of the shares subject to the Option vest on each monthly anniversary of the 2011 Vesting Commencement Date.

F4: Expiration date differs from originally reported date due to an automatic extension provided by the option plan as a result of the original expiration date falling during a Company blackout period and a lock-up agreement period.